Candidiasis, Oral Clinical Trial
Official title:
CelAgace™ OraRinse (CAOR) Pilot Clinical Study for Management of Candidiasis Associated With Grade 0-II Mucositis
CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.
CelAgace™ contains two active ingredients, a silver citrate complex salt (0.01mg/ml) that has demonstrated laboratory effectiveness against yeast organisms and acemannan (4.0mg/ml), a purified extract isolated from the inner leaf gel of the Aloe vera plant that has been used as a key ingredient in other oral care products. Patients will swish and spit the product 4 times daily (after meals and at bedtime) for 14 days. Following an initial office visit, patients will be evaluated on days 7 and 14 to determine response to the product. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004781 -
Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups
|
N/A | |
| Completed |
NCT03894839 -
Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species
|
N/A | |
| Completed |
NCT00128323 -
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis
|
Phase 3 | |
| Recruiting |
NCT04410250 -
Effect of Oral Hygienization in Newborn on Candida Spp Colonization
|
N/A | |
| Completed |
NCT02184351 -
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
|
Phase 3 | |
| Recruiting |
NCT03873753 -
Relationship Between Oral Hygiene in Newborns and Candida Spp.
|
N/A | |
| Completed |
NCT00665639 -
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
|
Phase 3 | |
| Completed |
NCT02818803 -
Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic
|
Phase 3 | |
| Recruiting |
NCT06120816 -
Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
|
Phase 1 | |
| Completed |
NCT00235053 -
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID
|
Phase 4 | |
| Completed |
NCT00666185 -
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
|
Phase 3 | |
| Completed |
NCT00002446 -
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
|
Phase 3 | |
| Completed |
NCT00001448 -
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection
|
N/A | |
| Completed |
NCT00612963 -
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
|
N/A | |
| Completed |
NCT00001812 -
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
|
Phase 3 | |
| Completed |
NCT00000951 -
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
|
Phase 4 | |
| Completed |
NCT00002341 -
A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole
|
N/A | |
| Completed |
NCT00002431 -
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
|
N/A | |
| Completed |
NCT00002293 -
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
|
N/A | |
| Completed |
NCT00002133 -
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.
|
N/A |